Eli Lilly (LLY) has filed six lawsuits against medical spas, a compounding pharmacy and other vendors over alleged counterfeit retatrutide sales, Axios reports

• The company is also referring thousands of sellers to regulators and law enforcement and urging payment processors and social-media platforms to restrict advertising and payments for the unapproved weight-loss drug

Lilly has form here: repeated waves of suits against compounders, telehealth outfits and med spas selling grey-market versions of its incretin franchise, with Novo running a parallel campaign on its own products. The read across those episodes is that litigation works less as a revenue event than as a channel-protection exercise, tightening the legal supply of copycat product and reinforcing the branded moat. This instance is cleaner than the compounding fights: retatrutide is unapproved, so there is no legitimate compounding carve-out to contest, and the counterfeit framing removes the regulatory ambiguity that has dogged shortage-era disputes. The escalation to regulators, law enforcement, payment processors and ad platforms follows the established sequence of squeezing distribution and payments rather than relying on court outcomes alone. Worth noting is that enforcement attention of this kind has historically intensified as the franchise matures and the maker seeks to defend pricing power ahead of pipeline launches. The follow-ons are whether platforms act on the referrals and whether regulators take up formal action, which is what has separated symbolic suits from actual channel closures in past rounds.